Search
Pradaxa-LongForm.pdf
synjardy-XR-LongForm.pdf
Tradjenta-LongForm.pdf
Trijardy-XR-LongForm.pdf
For Your SweetHeart Survey
For Your SweetHeart | Infographic
For Your SweetHeart | Campaign Facts
biah-us-overview-for-usda
Synjardy® (empagliflozin/metformin) Factsheet | PDF
PAP Eligibility Information
State of Connecticut Information
Dress For Your Day Guidelines
Advancing green chemistry for more sustainable medicines
By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
PAP Program Sales Force Info Flashcard
PAP Program information
Spanish-Enrollment-Form_0.pdf
EDITABLE-Spanish-Enrollment-form_3.pdf
New GPP Consensus Statement Released
National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)
Accessibility Statement
Boehringer Ingelheim endeavors to make https://www.boehringer-ingelheim.com accessible to any and all users.
FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
Deciphering Circuits in Neuroscience | Boehringer Ingelheim US
Hear from Craig Lindsley, Director of the Warren Center for Neuroscience Drug Discovery on our dedication to improving mental health.
Helping a Local Community in a Time of Need
Helping a Local Community in a Time of Need
Digital solutions save lives
Digital solutions save lives
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety